GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: compound B [WO2022002018A1] | LY-3499446
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: LY3499446 is a direct inhibitor of oncogenic KRAS mutant G12C that was developed for anticancer potential [1].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Uprety D, Adjei AA. (2020)
                                         KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev, 89: 102070. [PMID:32711246]  | 
                                                                
| 
                                                                         2. Yu S, Li B. (2022)
                                         Compound for inhibiting krasg12c mutant protein, preparation method therefor, and use thereof. Patent number: WO2022002018A1. Assignee: Suzhou Wentian Pharmaceutical Technology Co. Priority date: 03/07/2020. Publication date: 06/01/2022.  |